Peptidic Inhibitors and a Fluorescent Probe for the Selective Inhibition and Labelling of Factor XIIIa Transglutaminase
Molecules · 2023
DOI: 10.3390/molecules28041634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Eric W J Gates und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada. Hauptthemen laut MEDLINE: Transglutaminases, Factor XIIIa. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada (NSERC), Canadian Institutes of Health Research (CIHR).
Abstract (Originalsprache)
Factor XIIIa (FXIIIa) is a transglutaminase of major therapeutic interest for the development of anticoagulants due to its essential role in the blood coagulation cascade. While numerous FXIIIa inhibitors have been reported, they failed to reach clinical evaluation due to their lack of metabolic stability and low selectivity over transglutaminase 2 (TG2). Furthermore, the chemical tools available for the study of FXIIIa activity and localization are extremely limited. To combat these shortcomings, we designed, synthesised, and evaluated a library of 21 novel FXIIIa inhibitors. Electrophilic warheads, linker lengths, and hydrophobic units were varied on small molecule and peptidic scaffolds to optimize isozyme selectivity and potency. A previously reported FXIIIa inhibitor was then adapted for the design of a probe bearing a rhodamine B moiety, producing the innovative KM93 as the first known fluorescent probe designed to selectively label active FXIIIa with high efficiency (kinact/KI = 127,300 M−1 min−1) and 6.5-fold selectivity over TG2. The probe KM93 facilitated fluorescent microscopy studies within bone marrow macrophages, labelling FXIIIa with high efficiency and selectivity in cell culture. The structure–activity trends with these novel inhibitors and probes will help in the future study of the activity, inhibition, and localization of FXIIIa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
- Division of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, QC H3A 0C7, Canada.
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montréal, QC H3A 0C7, Canada.
ORCID-Profile: Eric W J Gates, Kian Mansour, Mari T Kaartinen, Jeffrey W Keillor
Förderung
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Canadian Institutes of Health Research (CIHR)
Zitieren
APA
Gates, E. W. J., Mansour, K., Ebrahimi Samani, S., Shad, S., Kaartinen, M. T., & Keillor, J. W. (2023). Peptidic Inhibitors and a Fluorescent Probe for the Selective Inhibition and Labelling of Factor XIIIa Transglutaminase. Molecules. https://doi.org/10.3390/molecules28041634
Vancouver
Gates EWJ, Mansour K, Ebrahimi Samani S, Shad S, Kaartinen MT, Keillor JW. Peptidic Inhibitors and a Fluorescent Probe for the Selective Inhibition and Labelling of Factor XIIIa Transglutaminase. Molecules. 2023. doi:10.3390/molecules28041634
BibTeX
@article{Gates2023,
author = {Gates, Eric W J and Mansour, Kian and Ebrahimi Samani, Sahar and Shad, Sammir and Kaartinen, Mari T and Keillor, Jeffrey W},
title = {Peptidic Inhibitors and a Fluorescent Probe for the Selective Inhibition and Labelling of Factor XIIIa Transglutaminase},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28041634}
}
EUVIMED